Catalio Capital Management and ARCH Venture Partners led a $76m Series A round in Pheast Therapeutics.

Catalio Capital Management, an investment company, and ARCH Venture Partners, a venture capital firm, led a $76m Series A round in Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, with participation from Alexandria Venture Investments. "While cancer immunotherapy has revolutionized the treatment of some tumors, many cancers, including ovarian and breast, have seen lackluster responses to existing immunotherapies, and patients are in dire need of new options. With the help of this funding, we will be much better equipped to increase and expand our research efforts, and in doing so, hopefully bring meaningful responses for treatment-resistant cancers closer to reality," Amira Barkal, Pheast Principal Founder, Scientific Director, and Interim CEO.